The public consultation period for the ICH E9 (R1) addendum on estimands and sensitivity analyses to the guideline on statistical principles for confirmatory clinical trials closed at the end of February 2018, and the addendum is planned to be issued in mid-2019.
At first glance the draft addendum can appear quite confusing – with a liberal sprinkling of statistical terminology such as ‘Estimand’, ‘Estimate’ and ‘Estimator’ it can be quite a dry document to digest (even for us statisticians). Moreover, there is a real risk that it is perceived as a ‘statisticians only’ document. This couldn’t be further from the truth and statisticians and clinicians cannot design or analyse trials in blissful isolation.
Recently, an FDA industry guidance draft on “Multiple Endpoints in Clinical Trials”  provided an overview of multiplicity which is a controversial topic. This is due to the practitioner’s common lack of clarity on when and how it arises and what adjustments to implement, such that the number of false positives, i.e. the type I error rate is constrained to a pre-specified level of significance alpha when performing inference for multiple hypothesis tests simultaneously . Once a trial is shown to be successful on the primary endpoint(s), there may be other attributes of the drug’s effect which are informative for inclusion in the physician labelling.
Multiplicity has to be accounted for when several tests are performed at the same time rather than just a single inference from a two treatment arm comparison for a single endpoint. Some of the reasons which lead to multiplicity include: (1) multiple primary endpoints which are each individually relevant to address the primary study objective, (2) more than two treatment arms, i.e. multiple treatments, combinations of treatments or different doses of same treatment, (3) repeated measurements, i.e. an outcome measurement is recorded at different time points for each patient, (4) interim analysis and (5) subgroup analyses where patient outcomes may vary when sub-setting by variables, such as biomarker status, age group or diabetes status.
On Tuesday 24th July 2018, PHASTAR presented a webinar on the topic 'Efficiencies when delivering a quality database'. The presenters were Sheelagh Aird, Head of Clinical Data Operations and Gillian Childs, Principal Data Coordinator. The webinar, hosted by X-talks and Medrio, demonstrated the importance of controlling the quality of a database right from study set-up.
The webinar introduced the use of the Data Quality Plan and the concept of identifying risk items and processes, defining quality, how quality is assessed and how it can be achieved. The presenters discussed how to select key personnel for ensuring quality and the processes to action and report on findings identified at data quality review timepoints.
PHASTAR will be in town for Biotech Week Boston, arriving on 4th September before attending BioPharm America on 5-6th and the CMO / CRO Symposium on the afternoon of the 6th.
Alternatively, if you're attending BioPharm America and would like to meet us then contact us using partneringONE.